DISC-3405

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera (PV)

Conditions

Polycythemia Vera (PV)

Trial Timeline

Aug 12, 2025 → Feb 1, 2029

NCT ID

NCT06985147

About DISC-3405

DISC-3405 is a phase 2 stage product being developed by Disc Medicine for Polycythemia Vera (PV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06985147. Target conditions include Polycythemia Vera (PV).

What happened to similar drugs?

2 of 17 similar drugs in Polycythemia Vera (PV) were approved

Approved (2) Terminated (1) Active (15)

✅HydroxyureaNovartisApproved

✅Ropeginterferon alfa-2bPharmaEssentiaApproved

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07187973	Phase 1	Recruiting	Jan 6, 2026	Oct 1, 2027	Sickle Cell Disease
NCT06985147	Phase 2	Recruiting	Aug 12, 2025	Feb 1, 2029	Polycythemia Vera (PV)

Competing Products

20 competing products in Polycythemia Vera (PV)

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	47
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Ruxolitinib + BAT	Novartis	Phase 2	39
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
Smac Mimetic LCL161	Novartis	Phase 2	35
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	39
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	40
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	35